The US deflazacort market is supported by the continued need for corticosteroid therapy in Duchenne muscular dystrophy (DMD), a rare progressive muscle disorder. Deflazacort is available in oral tablet and suspension formulations, providing treatment options for eligible patients. Growing attention to rare-disease management, expanded availability of generic formulations, and ongoing...